摘要
目的探讨心力衰竭患者神经内分泌激素和细胞因子的变化及缬沙坦对其影响。方法检测 4 8例心力衰竭患者及 2 0例健康者血内皮素 (ET 1)、血管紧张素Ⅱ (AngⅡ )和肿瘤坏死因子 α(TNF α)浓度。将 4 8例心力衰竭患者随机分为两组 :常规治疗组 2 6例 ,给予常规抗心力衰竭治疗 ;缬沙坦治疗组 2 2例 ,在常规治疗基础上加缬沙坦 80mg ,每日1次 ,两组患者均治疗 1个月。并设健康对照组 2 0例。观察ET 1、AngⅡ和TNF α治疗前后的变化。结果①心力衰竭患者ET 1、AngⅡ和TNF α水平显著高于对照组 (P <0 .0 1)。②两组患者治疗后心力衰竭症状均有明显改善 ,但以缬沙坦治疗后ET 1和TNF α水平下降显著 (P <0 .0 1)。结论神经内分泌激素及细胞因子与心力衰竭的发生、发展有关 ,缬沙坦治疗在改善心功能的同时 ,可降低心力衰竭患者神经内分泌激素和细胞因子水平。
Objective To explore the changes of neurocrine hormones and cytokine in the patients with congestive heart failure(CHF), and the effect of valsartan on them. Methods 48 CHF cases were randomly divided into two groups: conventional treatment group(n=26) which received routine therapy to treat CHF for 1month, and valsartan treatment group(n=22) which received valsartan 80mg/d in addition to routine therapy to treat CHF for 1 month. Another 20 healthy subjects were chosen as control group. The changes of ET-1, AngII and TNF-a were observed and detected. Results The levels of ET-1,AngII and TNF-a in CHF group were remarkably higher than that in control group(P<0.01). After treatment, the symptoms of CHF in the two groups were significantly improved, but ET-1,and TNF-a were significantly decreased after treatment with valsartan (P<0.01). Conclusion Both neurocrine hormone and cytokine are related with the development of CHF. In addition, valsartan can improve the cardiac function, while it can reduce the level of neurocrine hormone and cytokine in CHF patients.
出处
《中国综合临床》
北大核心
2003年第8期683-684,共2页
Clinical Medicine of China
